ARS Pharmaceuticals SPRY
NASDAQ SPRY
$5.62 -0.05 (-0.88%)
As of: Sep 4, 2026 · 3:59 PM EDT

ARS Pharmaceuticals (SPRY) EBT Margin Growth (1y) (2023 - 2026)

Analysis

ARS Pharmaceuticals (SPRY) EBT Margin Growth (1y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -153.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -571.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 553.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 4,709.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1,076.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1,911.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -392.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 29,565.00
10 ARS Pharmaceuticals 561.12 Mn 417.27 Mn 20.81 Mn 11,358.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11,358.00
Mar 31, 2026 19,123.00
Dec 31, 2025 -20,154.00
Sep 30, 2025 86,470.00
Jun 30, 2025 276,850.00
Jun 30, 2024 20.54 Mn
Jun 30, 2023 -20.71 Mn
Mar 31, 2023 -9.42 Mn